VKTX Viking Therapeutics Inc

$25.81

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 9/30/2025

About Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.

Website: https://www.vikingtherapeutics.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1607678
Address
12340 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, US
Valuation
Market Cap
$2.69B
P/E Ratio
nan
PEG Ratio
-0.03
Price to Book
3.05
Performance
EPS
$-1.01
Dividend Yield
—
Profit Margin
0.00%
ROE
-17.90%
Technicals
50D MA
$27.47
200D MA
$47.72
52W High
$81.86
52W Low
$18.92
Fundamentals
Shares Outstanding
112M
Target Price
$95.44
Beta
0.83

VKTX EPS Estimates vs Actual

● Estimated
● Actual

VKTX News & Sentiment

Sep 30, 2025 • Zacks Commentary NEUTRAL
Can NVO Maintain Obesity Leadership With Next-Generation Candidates?
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
Sep 30, 2025 • Motley Fool NEUTRAL
Why This Beaten-Down GLP-1 Stock Could Be a Steal
There's more to this company than its performance on the stock market this year suggests.
Sep 25, 2025 • Zacks Commentary NEUTRAL
Viking Therapeutics, Inc. ( VKTX ) Declines More Than Market: Some Information for Investors
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $25.09, indicating a -5.78% shift from the previous trading day.
Sep 25, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Brokers Suggest Investing in Viking Therapeutics ( VKTX ) : Read This Before Placing a Bet
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Sep 25, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?
VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.
Sep 25, 2025 • Motley Fool NEUTRAL
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.
Investors once speculated that Pfizer might consider acquiring Viking.
Sentiment Snapshot

Average Sentiment Score:

0.048
50 articles with scored sentiment

Overall Sentiment:

Neutral

VKTX Reported Earnings

Apr 22, 2025
Mar 31, 2025 (Pre market)
-0.1 Surprise
  • Reported EPS: $-0.41
  • Estimate: $-0.31
  • Whisper: —
  • Surprise %: -31.7%
Feb 05, 2025
Dec 31, 2024 (Post market)
-0.04 Surprise
  • Reported EPS: $-0.32
  • Estimate: $-0.28
  • Whisper: —
  • Surprise %: -14.3%
Oct 23, 2024
Sep 30, 2024 (Post market)
0.03 Surprise
  • Reported EPS: $-0.22
  • Estimate: $-0.25
  • Whisper: —
  • Surprise %: 12.0%
Jul 24, 2024
Jun 30, 2024 (Post market)
0.07 Surprise
  • Reported EPS: $-0.20
  • Estimate: $-0.27
  • Whisper: —
  • Surprise %: 25.9%
Apr 24, 2024
Mar 31, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $-0.26
  • Estimate: $-0.28
  • Whisper: —
  • Surprise %: 7.1%
Feb 07, 2024
Dec 31, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $-0.25
  • Estimate: $-0.25
  • Whisper: —
  • Surprise %: 0.0%
Oct 25, 2023
Sep 30, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.23
  • Estimate: $-0.22
  • Whisper: —
  • Surprise %: -4.5%
Jul 26, 2023
Jun 30, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $-0.19
  • Estimate: $-0.19
  • Whisper: —
  • Surprise %: 0.0%
Apr 26, 2023
Mar 31, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.25
  • Estimate: $-0.24
  • Whisper: —
  • Surprise %: -4.2%

Financials